Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas
详细信息 查看全文
- 作者：Anne-Katrin Zimmermann (1)
Jochen Imig (2)
Agnes Klar (3)
Christoph Renner (4)
Dimitri Korol (5)
Daniel Fink (6)
Sylvia Stadlmann (7)
Gad Singer (7)
Alexander Knuth (8)
Holger Moch (1)
Rosmarie Caduff (1) - 关键词：NY ; ESO ; 1 ; MAGE ; C1 ; GAGE ; CT7 ; Ovarian tumour ; Cancer/testis antigens
- 刊名：Virchows Archiv
- 出版年：2013
- 出版时间：May 2013
- 年：2013
- 卷：462
- 期：5
- 页码：565-574
- 全文大小：450KB
- 参考文献：1. Heintz AP, Odicino F, Maisonneuve P et al (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135-66 CrossRef
2. Odunsi K, Sabbatini P (2008) Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 59:62-4 CrossRef
3. Kandalaft LE, Powell DJ Jr, Singh N et al (2011) Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29:925-33 CrossRef
4. Simpson AJ, Caballero OL, Jungbluth A et al (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-25 CrossRef
5. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014-021 CrossRef
6. Brasseur F, Rimoldi D, Lienard D et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375-80 CrossRef
7. Kocher T, Zheng M, Bolli M et al (2002) Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100:702-05 CrossRef
8. Kurashige T, Noguchi Y, Saika T et al (2001) Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 61:4671-674
9. Patard JJ, Brasseur F, Gil-Diez S et al (1995) Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64:60-4 CrossRef
10. van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156-164
11. Davis ID, Chen W, Jackson H et al (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 101:10697-0702 CrossRef
12. Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669-74 CrossRef
13. Jager D, Jager E, Knuth A (2001) Vaccination for malignant melanoma: recent developments. Oncology 60:1- CrossRef
14. Jager E, Karbach J, Gnjatic S et al (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103:14453-4458 CrossRef
15. Sadanaga N, Nagashima H, Mashino K et al (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277-284
16. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1
17. Gillespie AM, Rodgers S, Wilson AP et al (1998) MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer 78:816-21 CrossRef
18. Russo V, Dalerba P, Ricci A et al (1996) MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas. Int J Cancer 67:457-60 CrossRef
19. Yamada A, Kataoka A, Shichijo S et al (1995) Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 64:388-93 CrossRef
20. Duan Z, Duan Y, Lamendola DE et al (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778-785
21. Egland KA, Kumar V, Duray P et al (2002) Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 1:441-50
22. Tammela J, Uenaka A, Ono T et al (2006) OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 29:903-10
23. Straughn JM Jr, Shaw DR, Guerrero A et al (2004) Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108:805-11 CrossRef
24. Tammela J, Jungbluth AA, Qian F et al (2004) SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 4:10
25. Tureci O, Sahin U, Zwick C et al (1998) Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95:5211-216 CrossRef
26. Valmori D, Qian F, Ayyoub M et al (2006) Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 12:398-04 CrossRef
27. Chen YT, Gure AO, Tsang S et al (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 95:6919-923 CrossRef
28. Odunsi K, Jungbluth AA, Stockert E et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076-083
29. Yakirevich E, Sabo E, Lavie O et al (2003) Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9:6453-460
30. Leffers N, Daemen T, Helfrich W et al (2010) Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007287.pub2
31. Liu B, Nash J, Runowicz C et al (2010) Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 3:7. doi:10.1186/1756-8722-3-7
32. Gjerstorff MF, Johansen LE, Nielsen O et al (2006) Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 94:1864-873 CrossRef
33. Cioca DP, Deak E, Cioca F et al (2006) Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells. J Immunother 29:41-2 CrossRef
34. Bolli M, Kocher T, Adamina M et al (2002) Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236:785-93, discussion 793 CrossRef
35. Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538-8543 CrossRef
36. Gure AO, Stockert E, Arden KC et al (2000) CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 85:726-32 CrossRef
37. Jungbluth AA, Chen YT, Busam KJ et al (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99:839-45 CrossRef
38. Noske A, Zimmermann AK, Caduff R et al (2011) Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch 459:91-7 CrossRef
39. Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7-5 CrossRef
40. Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175-81
41. Stadlmann S, Gueth U, Reiser U et al (2006) Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 19:607-10 CrossRef
42. Stadlmann S, Gueth U, Wight E et al (2007) Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol 60:307-10 CrossRef
43. Fossa A, Berner A, Fossa SD et al (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440-47 CrossRef
44. Lendvai N, Gnjatic S, Ritter E et al (2010) Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 10:4
45. Stockert E, Jager E, Chen YT et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-354 CrossRef
46. Curioni-Fontecedro A, Knights AJ, Tinguely M et al (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia 22:1646-648 CrossRef
47. Zhang S, Zhou X, Yu H et al (2010) Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10:163 CrossRef
48. Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-337 CrossRef
49. Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856-60 CrossRef
50. Fujita S, Wada H, Jungbluth AA et al (2004) NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 10:6551-558 CrossRef
51. Vaughan HA, Svobodova S, Macgregor D et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10:8396-404 CrossRef
52. Harrison ML, Jameson C, Gore ME (2008) Mucinous ovarian cancer. Int J Gynecol Cancer 18:209-14 CrossRef - 作者单位：Anne-Katrin Zimmermann (1)
Jochen Imig (2)
Agnes Klar (3)
Christoph Renner (4)
Dimitri Korol (5)
Daniel Fink (6)
Sylvia Stadlmann (7)
Gad Singer (7)
Alexander Knuth (8)
Holger Moch (1)
Rosmarie Caduff (1)
1. Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
2. Institute of Pharmaceutical Science, ETH Zurich, Wolfgang-Pauli-Str. 10, 8093, Zurich, Switzerland
3. Tissue Biology Research Unit, Department of Surgery, University Children’s Hospital, August-Forel-Str. 7, 8032, Zurich, Switzerland
4. Onkozentrum Hirslanden Zürich, Klinik Hirslanden, Witellikerstrasse 40, Zurich, 8032, Switzerland
5. Institute of Social and Preventive Medicine, University of Zurich, Vogelsangstrasse 10, 8091, Zurich, Switzerland
6. Department of Gynecology, University Hospital Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
7. Institute of Pathology, Kantonsspital Baden AG, 5404, Baden, AG, Switzerland
8. Clinic of Oncology, University Hospital Zurich, R?mistrasse 100, 8091, Zurich, Switzerland - ISSN：1432-2307
文摘
MAGE-C1/CT7, NY-ESO-1, GAGE and MAGE-A4 are members of the cancer/testis (CT) antigen family, which have been proposed as potential targets for cancer immunotherapy. To determine the prevalence and biologic relevance of the novel CT antigen MAGE-C1/CT7 and other antigens, 36 ovarian borderline tumours (BTs), 230 primary ovarian carcinomas (OCs) and 80 recurrent OCs were immunohistochemically analysed using the monoclonal antibodies CT7-33 (MAGE-C1/CT7), E978 (NY-ESO-1), clone 26 (GAGE) and 57B (MAGE-A4). Positivity of at least one CT antigen was present in 39.5?% (81/205) of primary OC and in 50?% (26/52) of all recurrences. Expression of the novel CT antigen MAGE-C1/CT7 was most commonly seen with positivity in 24.5?% of primary and 35.1?% of recurrent OC. MAGE-A4, GAGE and NY-ESO-1 expressions were seen in 22.7, 13.9 and 7.1?% of primary and 22.6, 17.5 and 8.9?% of recurrent OC, respectively. Analysis of histological subtypes (serous, endometrioid, clear cell, mucinous and transitional) exhibited variable expression with negativity in all mucinous OC. High-grade serous OC revealed CT antigen expression in 5.6 to 28?% with MAGE-C1/CT7 being the most frequent, but without correlation with stage or overall survival. MAGE-C1/CT7 expression and coexpression of CT antigens were significantly correlated with grade of endometrioid OC. None of the BT showed CT antigen expression. No significant correlation was seen with stage, overall survival or response to chemotherapy. In summary, CT antigens are expressed in a certain subset of OC with no expression in BT or OC of mucinous histology. These findings may have implications for the design of polyvalent vaccination strategies for ovarian carcinomas.